Workers Compensation
The 2026 Comcare National Conference brought more than 900 delegates to the National Convention Centre in Canberra from 14 to 16 September under the banner of a people-first approach to workplace health and safety. Independent Med Management and AllMeds were there with a stand, a concurrent session and one argument: medication is the most under-managed variable in workplace injury recovery, and the sector has the tools to change that.
Why was medication risk on the Comcare program?
Comcare's scheme covers Commonwealth agencies and self-insured licensees, a workforce where long-tail claims, secondary psychological conditions and complex medication regimens are familiar problems. The 2026 program's people-first theme was a natural fit for a question the sector rarely asks directly: how much of what we call a secondary condition is actually a medication adverse effect, and how much of a claim's tail is built one prescription at a time?
That was the premise of Concurrent Session C3, Medication Risk and Recovery Outcomes in Workplace Injury, presented by IMM Director and pharmacist Luke McGrath on Wednesday 16 September. The session sat in Track 3 alongside recovery and return-to-work content, which is where medication belongs. It is not a pharmacy topic. It is a recovery topic that happens to run through a pharmacy.
What did the C3 session argue?
The session made four connected points.
Medications tell a story no one is reading. A dispensing history is a timeline of clinical decisions, and read in sequence it shows where a claim turned. An opioid started in week one, a sleeping tablet in week six, an antidepressant in week twelve and a gabapentinoid in week twenty are not four unrelated treatment decisions. They are usually one decision, the first, and three responses to its consequences.
Adverse effect or secondary condition? The symptoms injured workers develop in the first months of a claim, fatigue, low mood, poor sleep, dizziness, constipation, cognitive fog, new pain, are the expected consequences of injury and also the documented adverse effects of the medications prescribed for it. When the second explanation is never tested, the symptom is given a diagnosis, the diagnosis gets a treatment, and the claim acquires a secondary condition it may never have needed. The mechanism is the prescribing cascade, and the worked example in the session traced a single wrist injury from week zero to week thirty as one prescription became three accepted conditions.
The window is early. The evidence on persistent opioid use, psychotropic escalation and claim duration points to the same period: the first twelve weeks. Intervention after week thirteen is remediation. Intervention before it is prevention, and it is cheaper, faster and better for the worker.
Governance needs a layer, not a heroic effort. Claims managers cannot read every dispensing history, and treating practitioners cannot see the whole regimen. What the scheme needs is a systematic screen that flags medication risk on every claim early, and an independent clinical arm that acts on the flags it raises. That is the division of labour between AllMeds and IMM.
How do AllMeds and IMM fit together?
AllMeds is the risk governance layer. It screens every claim before week twelve, scores medication risk from the dispensing and clinical data available, and identifies the claims where an adverse effect is likely to be on the way to becoming a diagnosis. The stand headline said it plainly: every claim screened prior to week twelve, before the adverse effect becomes a diagnosis. Matched intervention pathways are included in the cost of a clinical review, so a flag is never left without a next step.
Independent Med Management is the clinical arm that manages what the screen finds. IMM's pharmacists are independent of prescribers, dispensers and product suppliers. They review the regimen, assess causality for each symptom, quantify sedative and anticholinergic load, identify cascades and interdose withdrawal, and write recommendations that claims managers and treating practitioners can act on. Where a claim has already gone long, IMM's medication management program provides the ongoing pharmacist involvement needed to reverse a regimen that took months to build.
| Layer | What it does | When it acts |
|---|---|---|
| AllMeds | Screens every claim for medication risk and flags the ones heading toward an avoidable secondary condition | Before week twelve, on every claim |
| IMM pharmacy review | Independent clinical assessment of the flagged regimen, causality for each symptom, written recommendations | On referral, report returned within ten business days |
| IMM medication management | Ongoing pharmacist involvement to reverse cascades and support deprescribing on established claims | Long-tail and complex claims |
What was on the stand?
Three pieces travelled to Canberra. The main IMM piece was an A3 fold built around the question on its cover, medication adverse effect or a secondary condition, with the week-by-week narrative of a claim on the inside spread and the pattern cards that let a claims manager recognise the same story on their own files. A short AllMeds piece set out the trigger, assess, act sequence and the before-week-twelve screening promise. And the stand's booth screen ran a looped walk-through of the prescribing cascade and the IMM process for delegates who wanted the argument in ninety seconds rather than forty-five minutes.
The third piece was an offer. IMM's position at Comcare was that if a pharmacy review does not identify medication risks, make recommendations, support a decision and return within ten business days, it should not be paid for. The no results, no charge offer, code CC2026, is open to conference contacts until 1 July 2027. AllMeds offered a free screen on first claims under access code COMCARE101.
What does this mean for Comcare scheme participants?
For Commonwealth agencies and self-insured licensees, the practical implications are three. First, medication risk can be screened systematically rather than noticed by chance, and the screen can run on every claim rather than the ones that have already gone wrong. Second, a new symptom or diagnosis appearing in the first months of a claim should trigger one question before it triggers a treatment plan: could this be a medication effect? The framework for answering it is set out in IMM's guide to side effects versus new diagnoses, and the mechanism it interrupts is described in the article on prescribing cascades in personal injury claims. Third, independent pharmacist review is a scheme-level governance tool, not a last resort. Used early, it changes the trajectory of a claim. Used late, it still shortens the tail.
The conference's people-first theme and the medication risk argument are the same argument. An injured worker on six medications for an injury that needed two is not being put first, whatever the treatment plan says. Getting the medicines right, early and independently, is one of the few interventions that reduces claim cost and improves the worker's recovery at the same time.
What happens next?
Every conversation from the stand and the session is being followed up. Agencies and licensees who want to see the C3 content applied to their own portfolio can request the session material, a walk-through of the AllMeds screen on a sample of live claims, or a no-charge first IMM review under the conference offer. The offers stand until 1 July 2027 and the codes above apply.
Key Takeaways
- IMM and AllMeds presented at the 2026 Comcare National Conference in Canberra, 14 to 16 September, with a stand and Concurrent Session C3 on medication risk and recovery outcomes.
- The core argument: many secondary conditions on workplace injury claims are medication adverse effects that were never tested as such, and the prescribing cascade is how one prescription becomes three accepted conditions.
- The intervention window is the first twelve weeks. After that, medication review is remediation rather than prevention.
- AllMeds is the governance layer that screens every claim before week twelve; IMM is the independent clinical arm that reviews and manages what the screen finds.
- Conference offers: IMM no results, no charge pharmacy review (code CC2026) and a free AllMeds screen on first claims (access code COMCARE101), both open until 1 July 2027.
- For Comcare scheme participants, a new symptom in the first months of a claim should trigger the medication question before it triggers a treatment plan.
Frequently Asked Questions
What was IMM's session at the 2026 Comcare National Conference?
Concurrent Session C3, Medication Risk and Recovery Outcomes in Workplace Injury, presented by IMM Director and pharmacist Luke McGrath on Wednesday 16 September 2026 in Track 3. The session covered the prescribing cascade, the difference between a medication adverse effect and a secondary condition, the early intervention window and the governance model that AllMeds and IMM provide together.
What is the difference between AllMeds and Independent Med Management?
AllMeds is a medication risk governance platform that screens every claim early and flags the ones heading toward avoidable harm. Independent Med Management is the pharmacist-led clinical service that reviews flagged regimens, assesses causality and manages medication on complex and long-tail claims. AllMeds finds the risk; IMM manages it.
What is the Comcare conference offer and how long is it open?
IMM offered a no results, no charge pharmacy review to conference contacts: if the review does not identify medication risks, make recommendations, support a decision and return within ten business days, there is no fee. The code is CC2026. AllMeds offered a free screen on first claims under access code COMCARE101. Both are open until 1 July 2027.
Does IMM work with Comcare scheme agencies and self-insured licensees?
Yes. IMM provides independent clinical pharmacy review and medication management nationally across workers compensation, CTP and NDIS schemes, including Comcare scheme agencies and self-insured licensees. Referrals can be made through the IMM website.
Primary sources: 2026 Comcare National Conference program, National Convention Centre Canberra, 14 to 16 September 2026; IMM Concurrent Session C3 presentation material; Rochon and Gurwitz, The prescribing cascade revisited, Lancet 2017; Kalisch et al, Australian Prescriber 2011; Di Donato et al, early high-risk opioid prescribing in Australian workers, CNS Drugs 2025; Tefera et al, British Journal of Clinical Pharmacology 2026.
